Like many other breakthrough cancer medications, nivolumab is a drug that was first developed for more common types of cancer and is only now being tested for use in malignant mesothelioma. The drug is a monoclonal antibody that works as a checkpoint inhibitor: this means that it works to block a signal that cancer cells…
The post Phase 2 Clinical Trial of Nivolumab Use for Mesothelioma Shows Promise appeared first on Mesothelioma.net.
from Mesothelioma.net http://bit.ly/2S0cdaR
via IFTTT
Phase 2 Clinical Trial of Nivolumab Use for Mesothelioma Shows Promise
![Phase 2 Clinical Trial of Nivolumab Use for Mesothelioma Shows Promise]()
Reviewed by Unknown
on
January 22, 2019
Rating:
No comments: